Glaxo aims to lure patients from Novartis' Xolair with Nucala switching study

Nucala
GlaxoSmithKline's Nucala competes against Novartis' Xolair, Teva's Cinqair and AstraZeneca's Fasenra. (GlaxoSmithKline)

GlaxoSmithKline is taking direct aim at severe asthma challenger Xolair from Novartis.

Monday at the joint congress of the American Academy of Allergy, Asthma & Immunology and World Allergy Organization, the pharma giant rolled out data showing that switching uncontrolled Xolair patients to GSK’s Nucala improved asthma control.

Among switchers, the rate of exacerbations requiring oral steroids fell by 64% once taking Nucala, and researchers measured improvements in patients’ lung function and quality of life, too.

Virtual Roundtable

ESMO Post Show: Highlights from the Virtual Conference

Cancer experts and pharma execs will break down the headline-making data from ESMO, sharing their insights and analysis around the conference’s most closely watched studies. This discussion will examine how groundbreaking research unveiled over the weekend will change clinical practice and prime drugs for key new indications, and panelists will fill you in on the need-to-know takeaways from oncology’s hottest fields. Register today.

As many patients do, those enrolled in the study had asthma featuring both eosinophilic and allergic characteristics—making them eligible for treatment with either Nucala, which in 2015 became the first biologic therapy to bear a specific indication for severe eosinophilic asthma, or Xolair.

RELATED: GSK readies respiratory sales force to challenge Xolair in severe asthma

“This study is a valuable addition to our understanding of how to manage patients with biologic therapies,” study investigator Ken Champan said in a statement.

Glaxo, though, has more to worry about in terms of competition than just Xolair. While Teva’s Cinqair has been in the mix since March, 2016, the British drugmaker got what analysts view as more serious competition late last year.

The new challenger is AstraZeneca’s Fasenra, which, like Nucala, is administered subcutaneously. Unlike Nucala, it’s dosed just every eight weeks after the initial three doses, making it the longest-lasting therapy of the bunch.

RELATED: GlaxoSmithKline's Nucala, buoyed by its medical organization, ready to 'fiercely compete' with AstraZeneca

Glaxo, though, is counting on its big head start and its respiratory prowess to keep it on top in severe asthma, and some new indications wouldn’t hurt, either. The company is currently evaluating the drug in areas such as nasal polyps, and it’s filed for a COPD indication.

Suggested Articles

Last year at ESMO, AZ and Merck showed Lynparza topped its rivals at fending off prostate cancer. Now, Lynparza has helped patients live longer, too.

Merck and Eisai are trying to take their Keytruda-Lenvima combo into additional cancers, and new data provide a glimpse of where it might go next.

Bristol-Myers already has one Opdivo combo approved in kidney cancer, but it’s going for another—and new trial data could be just the ticket.